EP0906123A4 - OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA - Google Patents

OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA

Info

Publication number
EP0906123A4
EP0906123A4 EP97916760A EP97916760A EP0906123A4 EP 0906123 A4 EP0906123 A4 EP 0906123A4 EP 97916760 A EP97916760 A EP 97916760A EP 97916760 A EP97916760 A EP 97916760A EP 0906123 A4 EP0906123 A4 EP 0906123A4
Authority
EP
European Patent Office
Prior art keywords
oligonucleotides targeted
angiotensinogen mrna
angiotensinogen
mrna
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97916760A
Other languages
German (de)
French (fr)
Other versions
EP0906123A1 (en
Inventor
Donna Wielbo
M Ian Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Publication of EP0906123A1 publication Critical patent/EP0906123A1/en
Publication of EP0906123A4 publication Critical patent/EP0906123A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP97916760A 1996-03-15 1997-03-14 OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA Withdrawn EP0906123A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61686096A 1996-03-15 1996-03-15
PCT/US1997/004019 WO1997033623A1 (en) 1996-03-15 1997-03-14 OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA
US616860 2000-07-14

Publications (2)

Publication Number Publication Date
EP0906123A1 EP0906123A1 (en) 1999-04-07
EP0906123A4 true EP0906123A4 (en) 1999-05-26

Family

ID=24471266

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97916760A Withdrawn EP0906123A4 (en) 1996-03-15 1997-03-14 OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA

Country Status (5)

Country Link
EP (1) EP0906123A4 (en)
JP (1) JP2000506866A (en)
AU (1) AU2529697A (en)
CA (1) CA2248932A1 (en)
WO (1) WO1997033623A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9509798A (en) 1997-09-25 1999-04-12 University Of Florida Antisense oligonucleotide compositions targeted to angiotensi n converting enzy me mrna and methods of use
WO2014018930A1 (en) 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CA2998898A1 (en) * 2015-10-08 2017-04-13 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
CA3201661A1 (en) 2020-11-18 2022-05-27 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
CN113862268A (en) * 2021-10-20 2021-12-31 厦门甘宝利生物医药有限公司 AGT inhibitors and uses thereof
WO2023088227A1 (en) * 2021-11-16 2023-05-25 上海舶望制药有限公司 Composition and method for inhibiting angiotensinogen (agt) protein expression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030330A1 (en) * 1994-05-10 1995-11-16 Dzau Victor J Method for in vivo delivery of therapeutic agents via liposomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030330A1 (en) * 1994-05-10 1995-11-16 Dzau Victor J Method for in vivo delivery of therapeutic agents via liposomes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
COOK, J. ET AL.: "Identification and antisense inhibition of a renin-angiotensin system in transgenic cardiomyocytes", AM. J. PHYSIOL. (1995), 268(4, PT. 2), H1471-H1482, XP002098211 *
PHILLIPS, I. ET AL.: "Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes.", KIDNEY INT., vol. 46, 1994, pages 1554 - 1556, XP002098212 *
PHILLIPS, I.: "Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension", HYPERTENSION, vol. 29, January 1997 (1997-01-01), pages 177 - 187, XP002098214 *
See also references of WO9733623A1 *
UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE", CHEMICAL REVIEWS, vol. 90, no. 4, 1 June 1990 (1990-06-01), pages 543 - 584, XP000141412 *
WIELBO, D. ET AL.: "Antisense inhibition of hypertension in the spontaneously hypertensive rat", HYPERTENSION, vol. 25, 1995, pages 314 - 319, XP002098210 *
WIELBO, D. ET AL.: "Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides", HYPERTENSION, vol. 28, July 1996 (1996-07-01), pages 147 - 151, XP002098213 *

Also Published As

Publication number Publication date
WO1997033623A1 (en) 1997-09-18
CA2248932A1 (en) 1997-09-18
EP0906123A1 (en) 1999-04-07
AU2529697A (en) 1997-10-01
JP2000506866A (en) 2000-06-06

Similar Documents

Publication Publication Date Title
AU9023798A (en) Mdm2-specific antisense oligonucleotides
GB9620749D0 (en) Identifying antisense oligonucleotides
PL331854A1 (en) Phosphinamides as inhibitors of metaloprotease matrix
EP0983289A4 (en) Oligonucleotide adjuvant
SG74615A1 (en) Photocrosslinkable polymers
ZA98376B (en) Sulfamide-metalloprotease inhibitors
GB9510718D0 (en) Antisense oligonucleotides
GB2321641B (en) Sulfamide-metalloprotease inhibitors
HUP0300627A3 (en) Therapeutically useful synthetic oligonucleotides
AU5259498A (en) Antisense oligonucleotides
GB9505438D0 (en) Antisense oligonucleotides
GB9827958D0 (en) Biodegradable mat
GB2339855B (en) Distributor
GB9711919D0 (en) Oligonucleotide derivatives
TW418650U (en) Mat
EP0906123A4 (en) OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA
ZA988434B (en) New plant genes
EP0939130A4 (en) Rna polymerase
AU5093899A (en) Antisense oligonucleotides targeted to il-15
MA23595A1 (en) ANTISENSE OLIGONUCLEOTIDES
GB9711167D0 (en) Telomere-associated chromosome fragmentation
GB9810827D0 (en) Sanitising methods
GB9825687D0 (en) Oligonucleotide conjugation
CA2180077A1 (en) Rna polymerase inhibitors
PL331278A1 (en) Distributor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 980929;LT PAYMENT 980929;LV PAYMENT 980929;RO PAYMENT 980929;SI PAYMENT 980929

A4 Supplementary search report drawn up and despatched

Effective date: 19990413

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990625